Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666105 · ClinicalTrials.gov registry record · Phase 2
Exemestane in Post-Menopausal Women With NSCLC
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02666105 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 6 participants.
The verdict
NCT02666105, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
Interventions
- DRUG Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02666105
The ClinicalTrials.gov registry entry for NCT02666105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exemestane is the first listed.
NCT02666105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02666105 about?
NCT02666105 is a clinical study titled "Exemestane in Post-Menopausal Women With NSCLC". This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
What is the current status of trial NCT02666105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-09-27. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT02666105?
The interventions under investigation include: Exemestane (DRUG).
Who is sponsoring clinical trial NCT02666105?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.